Determination of Nitrosamine Impurities in Losartan Potassium Drug Substance Using Triple Quadrupole LC-MS
Poster Aug 05, 2020
Chander Mani, Saikat Banerjee and Samir Vyas (Agilent Technologies, India)
Nitrosamine impurities are byproducts produced in trace amounts during the manufacturing processes of angiotensin receptor blocking (ARB) medications. However, these impurities are classified as probable carcinogens, and so their discovery in and consequent recall of ARB drugs such as Losartan made N-Nitroso impurities a focus for many regulatory agencies.
Download this poster to discover a method that can provide a comprehensive analysis of nitrosamine impurities, showing excellent:
The changing landscape for antibody-derived therapeutics, such as bi-specific monoclonal antibodies, Fab fragments and Fc-fusion proteins brings new purification challenges in the downstream processing of these molecules. Standard chromatography resins, such as Protein A, may not result in the most efficient purification process.READ MORE